Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label selumetinib in Japanese pediatric NF1 with inoperable symptomatic plexiform neurofibromas
jRCT2080225326Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of selumetinib, Pharmacokinetics of selumetinib and 1 more. Started Aug 2020; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on jRCT2080225326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225326.